Combination Belviq/Phentermine in Medpage Article on Taste and Cravings
Obesity Week: A Matter of Taste
Published: Oct 30, 2014
By Kristina Fiore, Staff Writer, MedPage Today
It's not the gut, but the tongue that will be the focus of some of the top research at this year's Obesity Week conference.
A hot area of obesity research is in the connection between taste and obesity, according to Alison Field, ScD, of Boston Children's Hospital and a spokesperson for The Obesity Society. The meeting is presented jointly with the American Society for Metabolic and Bariatric Surgery.
Researchers will share data on how to help patients deal with food cravings -- a step toward a more personalized way of managing obesity, Field said.
"We're looking at food cues and how we can help people overcome them," she said. "It's about small behavioral changes people can make, that will make things like walking by a bakery less of a problem."
One group will present results on an intervention involving self-induced "distractions," and how these can affect food cravings, Field said.
Ninh Nguyen, MD, president of ASMBS and chief of gastrointestinal surgery at the University of California Irvine, highlighted a study that shows how patients who reported diminished taste intensity after bariatric surgery lost more weight than those whose sense of taste remained intense.
"It may be one mechanism by which people lose weight," Nguyen told MedPage Today.
The Skinny on Obesity Drugs
Now that three new obesity drugs -- Belviq (lorcaserin HCl), Qsymia (phentermine-topiramate), and Contrave (naltrexone-bupropion) -- are all on the market, participants will have a number of sessions to discuss how to best use these medications.
In addition to abstracts at poster sessions, there will be several symposia on the new pharmacologic landscape in obesity medicine.
One of those abstracts includes results of combining Belviq with phentermine, which was released by drugmaker Eisai ahead of the meeting.
In a 12-week study, 238 overweight and obese patients were randomized to either Belviq alone or to taking it in combination with phentermine either once or twice daily.
Researchers found no difference between groups in terms of the primary endpoint of having at least one of nine adverse events: headache, dizziness, nausea, fatigue, dry mouth, diarrhea, vomiting, insomnia, or anxiety.
Obesity Week: A Matter of Taste
Published: Oct 30, 2014
By Kristina Fiore, Staff Writer, MedPage Today
It's not the gut, but the tongue that will be the focus of some of the top research at this year's Obesity Week conference.
A hot area of obesity research is in the connection between taste and obesity, according to Alison Field, ScD, of Boston Children's Hospital and a spokesperson for The Obesity Society. The meeting is presented jointly with the American Society for Metabolic and Bariatric Surgery.
Researchers will share data on how to help patients deal with food cravings -- a step toward a more personalized way of managing obesity, Field said.
"We're looking at food cues and how we can help people overcome them," she said. "It's about small behavioral changes people can make, that will make things like walking by a bakery less of a problem."
One group will present results on an intervention involving self-induced "distractions," and how these can affect food cravings, Field said.
Ninh Nguyen, MD, president of ASMBS and chief of gastrointestinal surgery at the University of California Irvine, highlighted a study that shows how patients who reported diminished taste intensity after bariatric surgery lost more weight than those whose sense of taste remained intense.
"It may be one mechanism by which people lose weight," Nguyen told MedPage Today.
The Skinny on Obesity Drugs
Now that three new obesity drugs -- Belviq (lorcaserin HCl), Qsymia (phentermine-topiramate), and Contrave (naltrexone-bupropion) -- are all on the market, participants will have a number of sessions to discuss how to best use these medications.
In addition to abstracts at poster sessions, there will be several symposia on the new pharmacologic landscape in obesity medicine.
One of those abstracts includes results of combining Belviq with phentermine, which was released by drugmaker Eisai ahead of the meeting.
In a 12-week study, 238 overweight and obese patients were randomized to either Belviq alone or to taking it in combination with phentermine either once or twice daily.
Researchers found no difference between groups in terms of the primary endpoint of having at least one of nine adverse events: headache, dizziness, nausea, fatigue, dry mouth, diarrhea, vomiting, insomnia, or anxiety.
Belviq and Phen data
Aucun commentaire:
Enregistrer un commentaire